METHOD FOR PRODUCING PRODUCTION INTERMEDIATE, PRODUCTION INTERMEDIATE THEREOF, AND METHOD FOR PRODUCING CROSSLINKED ARTIFICIAL NUCLEIC ACID INTERMEDIATE BY USING SAME
A method for producing a compound of Formula (IV),
A method for producing a compound of Formula (IV),
A method for producing a compound of Formula (IV),
from a compound of Formula (I),
A method for producing a compound of Formula (IV),
from a compound of Formula (I),
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C07H 1/00 - Processes for the preparation of sugar derivatives
C07H 19/067 - Pyrimidine radicals with ribosyl as the saccharide radical
C07H 19/24 - Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
2.
COMPOUND AND PHARMACEUTICAL COMPOSITION FOR REGULATING MYOREGULIN EXPRESSION
Provided is a modified oligonucleotide having an activity of inhibiting myoregulin expression and comprising 12-30 linked nucleosides or a pharmaceutically acceptable salt of the modified oligonucleotide. The modified oligonucleotide comprises a base sequence 100% complementary to eight or more consecutive bases in a specific region of a base sequence represented by SEQ ID NO: 1 in the sequence listing. The full-length base sequence of the modified oligonucleotide is at least 85% complementarity to an equal length portion of the base sequence represented by SEQ ID NO: 1 in the sequence listing.
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations; pharmaceutical preparations for
treatment of erythropoietic protoporphyria and X-linked
protoporphyria. Providing medical information of erythropoietic
protoporphyria and X-linked protoporphyria; providing
medical information, consultancy and advisory services.
4.
PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF EDARAVONE AND METHOD OF ADMINISTERING SAME
A method of treating an oxidative stress disease includes orally or intragastrically administering, to a subject in need thereof, a pharmaceutical composition including edaravone with a time interval from a consumption of a meal by the subject in need thereof to an administration of the pharmaceutical composition to the subject in need thereof. The time interval is 8 hours or longer after the consumption of a high-fat meal, the time interval is 4 hours or longer after the consumption of a standard meal, or the time interval is 2 hours or longer after the consumption of a light meal.
This polypeptide is for improving the antigen-binding properties of an antigen-binding polypeptide in a cell. The polypeptide comprises 3 to 20 (inclusive) amino acid residues, wherein 57.0% to 100.0% (exclusive) of amino acid residues constituting the polypeptide comprises acidic amino acid residues. Also provided is a fusion polypeptide comprising the polypeptide and an antigen-binding polypeptide.
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations; pharmaceutical preparations for treatment of erythropoietic protoporphyria and X-linked protoporphyria. Providing medical information of erythropoietic protoporphyria and X-linked protoporphyria; providing medical information, consultancy and advisory services.
This pharmaceutical composition is for treating or preventing anti-neutrophil cytoplasmic antibody-associated vasculitis, and contains an anti-IL-33 antibody as an active ingredient. The pharmaceutical composition according to another embodiment is for reducing the need for surgery in endometriosis patients or adenomyosis uteri patients, and contains an IL-33 antagonist as an active ingredient. The pharmaceutical composition according to another embodiment is for treating or preventing endometriosis or adenomyosis uteri, contains an anti-IL-33 antibody as an active ingredient, is administered once every 2 to 8 weeks, and is administered so that the blood trough level of the anti-IL-33 antibody is 6.7 μg/mL or more.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
The present invention aims to provide a novel B0AT1 inhibitor. A compound represented by the following formula (I):
The present invention aims to provide a novel B0AT1 inhibitor. A compound represented by the following formula (I):
The present invention aims to provide a novel B0AT1 inhibitor. A compound represented by the following formula (I):
wherein each symbol is as defined in the SPECIFICATION, or a salt thereof. Also, the present invention provides a B0AT1 inhibitor containing the aforementioned compound, and a drug containing the aforementioned compound for the prophylaxis and/or treatment of amino acid metabolism disorders such as phenylketonuria, hypertyrosinemia (types 1-3), hypermethioninemia, maple syrup urine disease, homocystinuria, nonketotic hyperglycinemia, propionic acidemia, methylmalonic acidemia, isovaleric academia, and the like.
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
C07C 237/22 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
C07D 211/46 - Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07D 241/08 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
C07D 243/08 - Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
An information processing device includes a data acquisition part that acquires one or more neuromuscular disease-related user data selected from (a)-(k) multiple times in a predetermined period; and an information generation part that generates to-be-provided information to be provided to a predetermined terminal based on the user data. (a) Typing operation-related data, (b) walking-related data, (c) utterance-related data, (d) sleep-related data, (e) breathing-related data, (f) facial expression-related data, (g) fine motor movement-related data, (h) gross motor movement-related data, (i) questionnaire answers regarding disease symptoms, (j) information automatically collected with built-in sensors of devices, and (k) data from medical institutions.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 80/00 - ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
A method for evaluating responsiveness of a target to edaravone includes administering a composition including edaravone to a target in need thereof such that the edaravone causes a change in expression level of a gene product in the target, and evaluating whether the target has responsiveness to edaravone based on the change in expression level of the gene product due to exposure of the target to the edaravone, The gene product is a gene product of one or more genes selected from KAZALD1, SBK1, SCN2A, UBE2L6, ALPL, NTM, PTTG1, ITGB4, HAUS4, DCTD, MT2A, ASF1B, FCSK, MAST1 and FAIM2.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
A61K 31/4152 - 1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
15.
MEDICAL AGENT FOR TREATING OR SUPPRESSING PROGRESSION OF AMYOTROPHIC LATERAL SCLEROSIS
Disclosed is a medical agent for treating or suppressing progression of at least one symptom selected from a group consisting of amyotrophic lateral sclerosis and symptoms resulting from amyotrophic lateral sclerosis in a subject. The medical agent contains 3-methyl-1-phenyl-2-pyrazolin-5-one or a physiologically acceptable salt thereof, or a hydrate or solvate thereof. A blood uric acid level of the subject before administration of the medical agent is 4.2 mg/dL or higher.
A61K 31/4152 - 1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A medicament for treatment or prevention of interstitial lung disease, and of a disease or symptom accompanied by systemic sclerosis in a subject includes, as an effective ingredient, 1-{2-[(3S,4R)-1-{[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidin-3-yl]carbonyl}-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt or co-crystal thereof.
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
Provided is a preventive or therapeutic agent for associated symptoms accompanying a disease induced by a spinal cord or brain disorder, such as spinal cord injury and HTLV-1-associated myelopathy, the preventive or therapeutic agent containing an RGMa inhibition substance. Also provided is a preventive or therapeutic agent for spasm or neurogenic bladder dysfunction, the preventive or therapeutic agent containing an RGMa inhibition substance.
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 13/10 - Drugs for disorders of the urinary system of the bladder
A61P 21/02 - Muscle relaxants, e.g. for tetanus or cramps
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
19.
METHODS OF TREATING HYPERTENSION BY PERIODIC SUPPRESSION OF ALDOSTERONE SYNTHASE
This invention provides method of treating hypertension in a hypertensive subject, the method comprising administering to the subject a CYP 11β2 beta hydroxylase inhibitor once or twice per day in an amount sufficient to inhibit 50% or more of CYP 11β2 beta hydroxylase's activity for 40-60% of a 24-hour period to thereby treat hypertension in the hypertensive subject.
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
05 - Pharmaceutical, veterinary and sanitary products
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical preparations; pharmaceuticals; medicines for
human purposes; targeted protein degrader. Custom manufacture of pharmaceuticals. Testing, inspection or research of pharmaceuticals;
consulting services in the field of testing, inspection or
research of pharmaceuticals; providing medical and
scientific testing, inspection or research information in
the field of pharmaceuticals; conducting clinical trials for
pharmaceuticals; research and development services in the
field of pharmaceutical preparations.
A process for producing the compound IV or a salt thereof by the reaction represented by the following scheme; wherein the symbol is the same as described in the description; a process for producing 3-[4-[[trans-4-(acetamino)cyclohexyl]carbamoylmethyl]piperazin-1-yl]- 5-(p-tolyl)-1,2,4-triazine by the reaction represented by the following scheme: and a process for producing 3-[4-[[trans-4-(acetamino)cyclohexyl]carbamoylmethyl]piperazin-1-yl]- 5-(p-tolyl)-1,2,4-triazine by the reaction represented by the following scheme: wherein the symbol is the same as described in the description.
C07D 253/02 - Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group not condensed with other rings
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 253/065 - 1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
C07D 401/02 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
22.
METHOD FOR PRODUCING COMPOUND ENCODED BY OLIGONUCLEOTIDE, AND APPLICATION THEREOF
The purpose of the present invention is to provide a new method for producing a compound encoded by an oligonucleotide. Provided according to the present invention is a method for producing a compound encoded by an oligonucleotide, the method including phosphodiester bonding of oligonucleotide chains to each other by chemical ligation under prescribed conditions.
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
C40B 40/06 - Libraries containing nucleotides or polynucleotides, or derivatives thereof
C40B 50/10 - Liquid phase synthesis, i.e. wherein all library building blocks are in liquid phase or in solution during library creationParticular methods of cleavage from the liquid support involving encoding steps
23.
PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF EDARAVONE AND METHOD OF ADMINISTERING SAME
A method of treating an oxidative stress disease includes orally or intragastrically administering, to a subject in need thereof, a pharmaceutical composition including edaravone with a time interval from a consumption of a meal by the subject in need thereof to an administration of the pharmaceutical composition to the subject in need thereof. The time interval is 8 hours or longer after the consumption of a high-fat meal, the time interval is 4 hours or longer after the consumption of a standard meal, or the time interval is 2 hours or longer after the consumption of a light meal.
A method of treating an oxidative stress disease includes orally or intragastrically administering, to a subject in need thereof, a pharmaceutical composition including edaravone with a time interval from a consumption of a meal by the subject in need thereof to an administration of the pharmaceutical composition to the subject in need thereof. The time interval is 8 hours or longer after the consumption of a high-fat meal, the time interval is 4 hours or longer after the consumption of a standard meal, or the time interval is 2 hours or longer after the consumption of a light meal.
An information processing method includes, in a processing part of an information processing device that is connected to a user terminal device via a network: presenting a test related to fine motor movement to the user terminal device; generating an operation result according to an operation with respect to the test on the user terminal device having a touch panel; and generating to-be-provided information regarding a neuromuscular disease based on the operation result that has been acquired.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 80/00 - ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
26.
DRUG CONJUGATES OF cMET MONOCLONAL BINDING AGENTS, AND USES THEREOF
Presented herein are novel monoclonal cMET binding agents that are conjugated to pyrrolobenzodiazepine toxins, composition thereof and uses thereof for the treatment of cancer.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
05 - Pharmaceutical, veterinary and sanitary products
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical preparations; pharmaceuticals; medicines for human purposes; targeted protein degrader. Custom manufacture of pharmaceuticals. Testing, inspection or research of pharmaceuticals; consulting services in the field of testing, inspection or research of pharmaceuticals; providing medical and scientific testing, inspection or research information in the field of pharmaceuticals; conducting clinical trials for pharmaceuticals; research and development services in the field of pharmaceutical preparations.
28.
INFORMATION PROCESSING SYSTEM, INFORMATION PROCESSING METHOD, AND PROGRAM
[Problem] For easily discovering a disease status of NMOSD, and early detecting a recurrence sign from patient input data in the future, it is possible to provide the information processing system for visualizing a disease-related information on an optic nerve disease including a neuromyelitis optica spectrum disorder.
[Problem] For easily discovering a disease status of NMOSD, and early detecting a recurrence sign from patient input data in the future, it is possible to provide the information processing system for visualizing a disease-related information on an optic nerve disease including a neuromyelitis optica spectrum disorder.
[Solution] An information processing system of the present invention, comprises: a disease-related information acquisition part acquires a disease-related information including at least an optic nerve disease-related information of a subject; a visualization information addition part adds a visualization information generated based on the disease-related information including the optic nerve disease-related information to a first figure that representing a shape of at least a part of a human body; and a display information generation part generates a display information including a second figure that the visualization information is added to the first figure.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
A61B 3/02 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
A61K 33/06 - Aluminium, calcium or magnesiumCompounds thereof
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Provided is a compound or a pharmaceutically acceptable salt thereof which is superior in an action inducing degradation of BRD4 protein and useful as a therapeutic agent for cancer. A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof:
Provided is a compound or a pharmaceutically acceptable salt thereof which is superior in an action inducing degradation of BRD4 protein and useful as a therapeutic agent for cancer. A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof:
Provided is a compound or a pharmaceutically acceptable salt thereof which is superior in an action inducing degradation of BRD4 protein and useful as a therapeutic agent for cancer. A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof:
wherein each symbol is as defined in the DESCRIPTION.
A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
The present invention addresses the problem of providing: a novel compound capable of effectively inhibiting all of SIK1, SIK2, and SIK3; and a pharmaceutical composition containing the same. Provided is a compound represented by formula (I): [in the formula, each symbol is as described in the description] or a pharmacologically acceptable salt thereof.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 5/00 - Drugs for disorders of the endocrine system
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
The specification generally relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where R1, R2A, R2B, R2C, R2D, W, X, Y, and Z have the meanings defined herein. Such compounds are useful in inhibiting NLRP3 inflammasome activity and may be useful as therapeutic agents. The specification also relates to the use of such compounds to treat or prevent diseases and conditions in which the NLRP3 inflammasome is implicated. The specification further relates to compositions comprising such compounds.
The specification generally relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where R1, R2A, R2B, R2C, R2D, W, X, Y, and Z have the meanings defined herein. Such compounds are useful in inhibiting NLRP3 inflammasome activity and may be useful as therapeutic agents. The specification also relates to the use of such compounds to treat or prevent diseases and conditions in which the NLRP3 inflammasome is implicated. The specification further relates to compositions comprising such compounds.
Disclosed are pharmaceutical compositions comprising a salt of a compound having the formula:
Disclosed are pharmaceutical compositions comprising a salt of a compound having the formula:
Disclosed are pharmaceutical compositions comprising a salt of a compound having the formula:
and one or more excipients, wherein the pharmaceutical composition avoids inducing disproportionation of the salt of the compound.
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
Provided is a method for predicting the efficacy of a bispecific fusion polypeptide in a subject, the method comprising comparing the level of a biomarker molecule in a sample taken from a subject with a cut-off value for the biomarker molecule. In the method: the subject is suffering from systemic sclerosis; the biomarker molecule is at least one biomarker molecule selected from the group consisting of IL-6, GDF15, LTBP2, CCL7, CHI3L1, EFEMP1, PLAUR, and SPON1; and the bispecific fusion polypeptide binds to IL-17a and includes a finomer sequence that forms a complex with an antibody that binds to IL-6R or with a partial sequence thereof that has IL-6R binding ability.
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
The purpose of the present invention is to provide a novel B0AT1 inhibitor. The present invention pertains to a compound, or a salt thereof, having an inhibitory action on B0AT1, the compound being represented by formula (I) [the symbols in the formula are as defined in the description]. The present invention also pertains to: a B0AT1 inhibitor containing the compound; and a pharmaceutical composition containing the compound. One embodiment of the present invention is a medical drug that is suitable for preventing and/or treating, for example, amino acid metabolism disorders such as phenylketonuria, urea cycle disorders, hypertyrosinemia (type 1-3), hypermethioninemia, maple syrup urine disease, homocystinuria, nonketotic hyperglycinemia, propionic acidemia, methylmalonic acidemias, and isovaleric acidemia.
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
A61K 31/499 - Spiro-condensed pyrazines or piperazines
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
A61P 13/02 - Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07D 209/08 - IndolesHydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
C07D 209/26 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
C07D 211/34 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 211/70 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 217/06 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ringAlkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
C07D 217/16 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
C07D 217/22 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07D 241/42 - Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
A composition for use in treatment or prevention of a TAR DNA-binding protein 43 related disease, comprising a promoting substance that increases an intracellular amount of a protein having ubiquitination activity.
Provided is a pharmaceutical composition for treating multisystem atrophy or inhibiting the progression of multisystem atrophy, or for extending the survival period of a multisystem atrophy patient. Disclosed is a pharmaceutical composition for treating multisystem atrophy or inhibiting the progression of multisystem atrophy, or for extending the survival period of a patient having multisystem atrophy, the pharmaceutical composition containing a DPP4 inhibitor.
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61K 31/382 - Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 43/00 - Drugs for specific purposes, not provided for in groups
Provided is an anti-PAD4 antibody or an antibody fragment thereof, wherein HCDR1 comprises an amino acid sequence of SEQ ID NO: 1, HCDR2 comprises an amino acid sequence of SEQ ID NO: 2, HCDR3 comprises an amino acid sequence of SEQ ID NO: 3, LCDR1 comprises an amino acid sequence of SEQ ID NO: 4, LCDR2 comprises an amino acid sequence of SEQ TD NO: 5, and LCDR3 comprises an amino acid sequence of SEQ ID NO: 6.
This invention provides an agent for preventing or treating acute phase neuromyelitis optica, and pain symptoms in neuromyelitis optica, which comprises a RGMA inhibiting substance.
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
40.
3, 5-disubstituted pyridine and 3, 5-disubstituted pyridazine derivatives and pharmaceutical use of same
A method for treating or preventing a disease involving autotaxin including administering a carboxylic acid compound of formula (1)
or a pharmacologically acceptable salt thereof to a patient in need thereof.
A61P 11/00 - Drugs for disorders of the respiratory system
C07D 213/89 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
C07D 237/08 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
41.
CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR
The problem addressed is to provide a novel compound having cereblon E3 ligase binding ability. Provided is a compound represented by formula (I): [in the formula, the symbols are as described in the specification.], formula (II): [in the formula, the symbols are as described in the specification.], formula (III): [in the formula, the symbols are as described in the specification.], or formula (IV): [in the formula, the symbols are as described in the specification.] or a pharmaceutically acceptable salt thereof.
A61K 31/45 - Non-condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07D 243/04 - Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 3
C07D 267/10 - Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
The specification generally relates to crystalline forms of inhibitors of the NLRP3 inflammasome, pharmaceutical compositions comprising such crystalline forms, chemical processes useful for the preparation of inhibitors of the NLRP3 inflammasome, and intermediate compounds useful in such processes. Such crystalline forms and pharmaceutical compositions are useful in inhibiting NLRP3 inflammasome activity and may be useful as therapeutic agents.
C07D 237/32 - Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
C07D 237/34 - Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
C07D 309/12 - Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07C 65/40 - Compounds having carboxyl groups bound to carbon atoms of six-membered aromatic rings and containing any of the groups OH, O-metal, —CHO, keto, ether, groups, groups, or groups containing keto groups containing singly bound oxygen-containing groups
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 37/00 - Drugs for immunological or allergic disorders
A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
The specification generally relates to compounds of Formula (I), Formula (II) and Formula (VI), and pharmaceutically acceptable salts thereof. Such compounds are useful in inhibiting NLRP3 inflammasome activity and may be useful as therapeutic agents. The specification also relates to the use of such compounds to treat or prevent diseases and conditions in which the NLRP3 inflammasome is implicated. The specification further relates to compositions comprising such compounds. (Formula (I) Formula (II) Formula (VI))
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 37/00 - Drugs for immunological or allergic disorders
A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
45.
METHOD FOR PRODUCING PRODUCTION INTERMEDIATE, PRODUCTION INTERMEDIATE THEREOF, AND METHOD FOR PRODUCING CROSSLINKED ARTIFICIAL NUCLEIC ACID INTERMEDIATE BY USING SAME
The present invention addresses the problem of providing: a method for producing a production intermediate which is safe and advantageous for industrial production; a production intermediate thereof; and a method for producing a crosslinked artificial nucleic acid intermediate by using the same. The present invention includes a method for producing a compound represented by formula (IV) [in the formula, the symbols are as defined in the specification] from a compound represented by formula (I) [in the formula, the symbols are as defined in the specification].
C07H 15/18 - Acyclic radicals, substituted by carbocyclic rings
C07H 1/00 - Processes for the preparation of sugar derivatives
C07H 19/067 - Pyrimidine radicals with ribosyl as the saccharide radical
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
46.
PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF EDARAVONE AND METHOD OF ADMINISTERING SAME
A method of treating an oxidative stress disease includes orally or intragastrically administering, to a subject in need thereof, a pharmaceutical composition including edaravone with a time interval from a consumption of a meal by the subject in need thereof to an administration of the pharmaceutical composition to the subject in need thereof. The time interval is 8 hours or longer after the consumption of a high-fat meal, the time interval is 4 hours or longer after the consumption of a standard meal, or the time interval is 2 hours or longer after the consumption of a light meal.
A61K 31/4152 - 1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
A61K 9/00 - Medicinal preparations characterised by special physical form
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
47.
AGENT FOR PREVENTING OR TREATING DISEASE ASSOCIATED WITH ACCUMULATION OF ABNORMAL PROTEIN AGGREGATES
Provided is an agent containing an RGMa inhibition substance, the agent being for suppressing accumulation of abnormal protein aggregates or for inhibiting uptake of abnormal proteins by nerve cells, particularly for preventing or treating disease associated with accumulation of abnormal protein aggregates.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
[Problem] An information processing device capable of predicting a timing of appearing a symptom related to photosensitivity in a patient with photosensitivity, is provided.
[Problem] An information processing device capable of predicting a timing of appearing a symptom related to photosensitivity in a patient with photosensitivity, is provided.
[Solution] An information processing device comprising:
an acquisition unit acquires a reference information set including one or more reference information selected from below (a) to (l), in addition an environmental data; and
a generation unit generates, based on the environmental data and the reference information set, a provision information for providing to a predetermined terminal;
(a) a daylight hour until appearing a photosensitivity related symptom
(b) a timing of the photosensitivity related symptom
(c) a grade of the photosensitivity related symptom
(d) PGIC (Patient Global Impression of Change) score
(e) a skin pigment information
(f) a melanin density
(g) a quantity of a protoporphyrin in a blood
(h) a type of a medicine
(i) a prescription quantity of a medicine
(j) Fitzpatrick skin type
(k) PGIS score (Patient Global Impression Severity)
(l) a data acquired by PROMIS (Patient-Reported Outcomes Measurement Information System).
G16H 70/60 - ICT specially adapted for the handling or processing of medical references relating to pathologies
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
49.
ANTI-ADIPONECTIN RECEPTOR ANTIBODY AND UTILIZATION OF SAME
Provided is an anti-adiponectin antibody or an antibody fragment thereof in which LCDR1 includes an amino acid sequence of SEQ ID NO: 17 or 18, LCDR2 includes an amino acid sequence of SEQ ID NO: 19 or 20, LCDR3 includes an amino acid sequence of SEQ ID NO: 21, HCDR1 includes an amino acid sequence of SEQ ID NO: 22, HCDR2 includes an amino acid sequence of SEQ ID NO: 23, and HCDR3 includes an amino acid sequence of SEQ ID NO: 24.
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention provides: a methyl 1-{2-[(3S,4R) -1-[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4 -methoxyphenyl)pyrrolidine-3-carbonyl]-4 -(methoxymethyl)pyrrolidin-3-yl]-5 -(trifluoromethyl)phenyl}piperidine-4-carboxylate 1/2 ethane-1,2-disulfonic acid which is represented by formula (1) and is excellent in crystallinity; and a method for producing the same; and a production intermediate thereof;
The present invention provides: a methyl 1-{2-[(3S,4R) -1-[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4 -methoxyphenyl)pyrrolidine-3-carbonyl]-4 -(methoxymethyl)pyrrolidin-3-yl]-5 -(trifluoromethyl)phenyl}piperidine-4-carboxylate 1/2 ethane-1,2-disulfonic acid which is represented by formula (1) and is excellent in crystallinity; and a method for producing the same; and a production intermediate thereof;
and a production method using this compound.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
The present invention relates to an orally disintegrating tablet. As one embodiment, the present invention relates to an orally disintegrating tablet which comprises 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene or a pharmaceutically acceptable salt thereof, or a hydrate of the compound or the pharmaceutically acceptable salt thereof. As another embodiment, the present invention relates to an orally disintegrating tablet which comprises 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene or a pharmaceutically acceptable salt thereof, or a hydrate of the compound or the pharmaceutically acceptable salt thereof, an excipient, and a lubricant, and has a proper level of strength and rapid disintegrating properties in oral cavity.
A method for treating amyotrophic lateral sclerosis includes administering an effective amount of 3-methyl-1-phenyl-2-pyrazolin-5-one or a physiologically acceptable salt thereof to a patient who is in need thereof and meets two or more features selected from a group of identified features.
A61K 31/4152 - 1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
54.
PHARMACEUTICAL COMPOSITION CONTAINING 1-{2-[(3S,4R)-1-{[(3R,4R)-1-CYCLOPENTYL-3-FLUORO-4-(4-METHOXYPHENYL)PYRROLIDINE-3-YL]CARBONYL}-4-(METHOXYMETHYL)PYRROLIDINE-3-YL]-5-(TRIFLUOROMETHYL)PHENYL}PIPERIDINE-4-CARBOXYLIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT OR CO-CRYSTAL THEREOF
Provided is a pharmaceutical composition containing, as an active ingredient, 1-{2-[(3S,4R)-1-{[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidine-3-yl]carbonyl}-4-(methoxymethyl)pyrrolidine-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylic acid (compound A) or a pharmaceutically acceptable salt or co-crystal thereof, wherein the content of the compound A is at least 30 wt% based on the total weight of the pharmaceutical composition and the pharmaceutical composition is preferably obtained by a production method which includes a granulation step for obtaining a granulated product by spraying a binding liquid, which includes the compound A or a pharmaceutically acceptable salt or co-crystal thereof and a binding agent, onto a powder, which includes the compound A or a pharmaceutically acceptable salt or co-crystal thereof, in a fluidized bed granulator.
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
An antibody has an antagonistic effect against IL-33. An isolated human anti-IL-33 neutralizing monoclonal antibody has framework regions with amino acid sequences from a germline, including combinations and fragments of such sequences. The epitopes for a plurality of anti-IL-33 monoclonal antibodies were identified, human anti-IL-33 neutralizing monoclonal antibodies were obtained, and the complementarity-determining regions that achieve high binding ability to IL-33 was specified by introducing mutations in the complementarity-determining regions. The identified complementarity-determining regions were used to produce the foregoing human anti-IL-33 neutralizing monoclonal antibodies having framework regions.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
58.
COMPOSITION AND METHOD FOR EVALUATING RESPONSIVENESS OF EDARAVONE
The composition according to the present disclosure includes edaravone and is used to change the expression level of a gene product in a target. The gene product is a gene product from one or more genes selected from KAZALD1, SBK1, SCN2A, UBE2L6, ALPL, NTM, PTTG1, ITGB4, HAUS4, DCTD, MT2A, ASF1B, FCSK, MAST1, and FAIM2. The composition is also preferably used as a medicine. The composition is also preferably used for treatment or prevention of a neurodegenerative disease. The neurodegenerative disease is preferably amyotrophic lateral sclerosis (ALS). The present disclosure also provides a method for evaluating responsiveness of edaravone on the basis of an expression level of the gene product or a change in the expression level.
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
A61K 31/4152 - 1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The specification generally relates to solid forms, for example, crystalline and amorphous forms, of (1S,4s)-4-(2-fluoro-4-methoxy-5-(((1S,2R,3S,4R)-3-(((1- methylcyclobutyl)methyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl)carbamoyl)phenoxy)-1- methylcyclohexane-1-carboxylic acid (Compound (I)). In particular, an amorphous form of Compound (I), solid dispersions and pharmaceutical compositions comprising such an amorphous form, and crystalline Form G of Compound (I).
C07C 237/52 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the nitrogen atom of at least one of the carboxamide groups further acylated
A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
60.
INFORMATION PROCESSING SYSTEM, INFORMATION PROCESSING METHOD, PROGRAM, AND RECORDING MEDIUM
[Problem] The present invention makes it possible to provide an information processing system for generating sleep-inertia-like symptom information on the basis of activity level information of a subject 40 of measurement, measured by means of a measurement device, in order to make it possible to readily check sleep-inertia-like symptoms. [Solution] An information processing system according to the present invention is characterized by being provided with: an activity-level acquisition unit that acquires activity level information of a subject of measurement, measured by means of a measurement device; an awakening-status estimation unit that estimates the awakening status of the subject of measurement; and a sleep-inertia-like symptom information generation unit that generates, at least on the basis of the activity level information after the awakening status is estimated as being awake, sleep-inertia-like symptom information relating to sleep-inertia-like symptoms appearing with the subject of measurement.
G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
A61B 5/16 - Devices for psychotechnicsTesting reaction times
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Rental of smartphones; Rental of smartphones featuring embedded software for detecting symptoms of ALS, sold as a unit; Rental of smartphones featuring embedded software for measuring progress of ALS, sold as a unit; Rental of smartphones featuring embedded software for tracking change of fine motor skills, sold as a unit; Rental of smartphones featuring embedded software for diagnosing ALS, sold as a unit; Rental of smartphones featuring embedded software for testing fine motor skills, sold as a unit; Rental of smartphones featuring embedded software for collecting test data of fine motor skills of patients with ALS and providing the data to clinicians, sold as a unit; Rental of mobile phones Downloadable software for detecting symptoms of ALS; Downloadable software for measuring progress of ALS; Downloadable medical software for tracking change of fine motor skills; Downloadable medical software for diagnosing ALS; Downloadable medical software for testing fine motor skills; Downloadable medical software for collecting test data of fine motor skills of patients with ALS and providing the data to clinicians; Software as a Medical Device (SaMD), downloadable, for detecting symptoms of ALS; Software as a Medical Device (SaMD), downloadable, for measuring progress of ALS; Software as a Medical Device (SaMD), downloadable, for tracking change of fine motor skills; Software as a Medical Device (SaMD), downloadable, for diagnosing ALS; Software as a Medical Device (SaMD), downloadable, for testing fine motor skills; Software as a Medical Device (SaMD), downloadable, for collecting test data of fine motor skills of patients with ALS and providing the data to clinicians Software as a service (SaaS) services featuring non-downloadable software for detecting symptoms of ALS; Software as a service (SaaS) services featuring non-downloadable software for measuring progress of ALS; Software as a service (SaaS) services featuring non-downloadable medical software for tracking change of fine motor skills; Software as a service (SaaS) services featuring non-downloadable medical software for diagnosing ALS; Software as a service (SaaS) services featuring non-downloadable medical software for testing fine motor skills; Software as a service (SaaS) services featuring non-downloadable medical software for collecting test data of fine motor skills of patients with ALS and providing the data to clinicians; Providing on-line non-downloadable software for medical purposes for detecting symptoms of ALS; Providing on-line non-downloadable software for medical purposes for measuring progress of ALS; Providing on-line non-downloadable medical software for tracking change of fine motor skills; Providing on-line non-downloadable medical software for diagnosing ALS; Providing on-line non-downloadable medical software for testing fine motor skills; Providing on-line non-downloadable medical software for collecting test data of fine motor skills of patients with ALS and providing the data to clinicians; Rental of computer hardware and computer peripherals; Rental of tablet computers
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Rental of smartphones; Rental of smartphones featuring embedded software for detecting symptoms of ALS, sold as a unit; Rental of smartphones featuring embedded software for measuring progress of ALS, sold as a unit; Rental of smartphones featuring embedded software for tracking change of fine motor skills, sold as a unit; Rental of smartphones featuring embedded software for diagnosing ALS, sold as a unit; Rental of smartphones featuring embedded software for testing fine motor skills, sold as a unit; Rental of smartphones featuring embedded software for collecting test data of fine motor skills of patients with ALS and providing the data to clinicians, sold as a unit; Rental of mobile phones Downloadable software for detecting symptoms of ALS; Downloadable software for measuring progress of ALS; Downloadable medical software for tracking change of fine motor skills; Downloadable medical software for diagnosing ALS; Downloadable medical software for testing fine motor skills; Downloadable medical software for collecting test data of fine motor skills of patients with ALS and providing the data to clinicians; Software as a Medical Device (SaMD), downloadable, for detecting symptoms of ALS; Software as a Medical Device (SaMD), downloadable, for measuring progress of ALS; Software as a Medical Device (SaMD), downloadable, for tracking change of fine motor skills; Software as a Medical Device (SaMD), downloadable, for diagnosing ALS; Software as a Medical Device (SaMD), downloadable, for testing fine motor skills; Software as a Medical Device (SaMD), downloadable, for collecting test data of fine motor skills of patients with ALS and providing the data to clinicians Software as a service (SaaS) services featuring non-downloadable software for detecting symptoms of ALS; Software as a service (SaaS) services featuring non-downloadable software for measuring progress of ALS; Software as a service (SaaS) services featuring non-downloadable medical software for tracking change of fine motor skills; Software as a service (SaaS) services featuring non-downloadable medical software for diagnosing ALS; Software as a service (SaaS) services featuring non-downloadable medical software for testing fine motor skills; Software as a service (SaaS) services featuring non-downloadable medical software for collecting test data of fine motor skills of patients with ALS and providing the data to clinicians; Providing on-line non-downloadable software for medical purposes for detecting symptoms of ALS; Providing on-line non-downloadable software for medical purposes for measuring progress of ALS; Providing on-line non-downloadable medical software for tracking change of fine motor skills; Providing on-line non-downloadable medical software for diagnosing ALS; Providing on-line non-downloadable medical software for testing fine motor skills; Providing on-line non-downloadable medical software for collecting test data of fine motor skills of patients with ALS and providing the data to clinicians; Rental of computer hardware and computer peripherals; Rental of tablet computers
64.
Sulfonamide or sulfinamide compound having effect of inducing BRD4 protein degradation and pharmaceutical use thereof
Provided is a compound or a pharmaceutically acceptable salt thereof which is superior in an action inducing degradation of BRD4 protein and useful as a therapeutic agent for cancer. A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof:
wherein each symbol is as defined in the DESCRIPTION.
A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
Analysis method of 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient, treatment for amyotrophic lateral sclerosis, inhibition of progression of amyotrophic lateral sclerosis, and method of producing medicament containing 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient
A method of analyzing phenylhydrazine content in a 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient includes obtaining a first measured value by measuring a phenylhydrazine content of a standard solution including phenylhydrazine or a salt thereof, a first acidic water and a first water-soluble organic solvent and having a phenylhydrazine concentration of 0.01 μg/mL to 10 μg/mL, obtaining a second measured value by measuring a phenylhydrazine content in a sample solution including a 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient, a second acidic water and a second water-soluble organic solvent, and detecting a phenylhydrazine content in a 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient based on the first measured value and second measured value. The first acidic water includes hydrochloric acid, the first water-soluble organic solvent is acetonitrile and/or methanol, the second acidic water includes hydrochloric acid, and the second water-soluble organic solvent is acetonitrile and/or methanol.
The present invention provides a salt of a triazine compound which has an inhibitory action against aldosterone synthase and is useful as a drug, and especially as a drug for preventing or treating primary aldosteronism and the like, a crystal thereof, and a method for producing the same. Specifically, the present invention provides a pharmaceutically acceptable salt of 3-[4-[[trans-4-(acetamino)cyclohexyl]carbamoylmethyl]piperazin-1-yl]-5-(p-tolyl)-1,2,4-triazine, wherein the salt is hydrobromide, sulfate, succinate, or tosilate, and the like.
C07D 253/07 - 1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
A neuromuscular disease evaluation device that is less invasive, highly sensitive, quantitative and objective, and capable of easily evaluating neuromuscular diseases. A device for evaluating motor functions related to neuromuscular diseases, comprising: a memory unit storing a reference value for evaluating a predetermined movement, which is calculated based on a position of at least one body part; an analysis unit for identifying a position of a body part of the user by analyzing information based on an image captured of the predetermined movement, including the user's body; and an evaluation unit for evaluating the motor function based on the numerical value calculated based on the position of the body part of the user and the reference value.
The specification generally relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where A, U, V, W, X, Y, Z, R1, R2, R3, R4 and R5 have the meanings defined herein. Such compounds are modulators of RXFP1 and may be useful as therapeutic agents. The specification also relates to the use of such compounds to treat or prevent diseases and conditions including heart failure, heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, heart failure with reduced ejection fraction, chronic kidney disease and acute kidney injury. The specification further relates to compositions comprising such compounds, intermediates useful in processes for preparing such compounds, and processes for preparing such compounds using such intermediates.
C07C 233/81 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
70.
INFORMATION PROCESSING SYSTEM, INFORMATION PROCESSING METHOD, AND PROGRAM
[Problem] To provide an information processing system that presents a medication notification based on a diet restriction period, to thereby make it possible to present a medication notification corresponding to medicines having different diet restriction periods in accordance with, in particular, the type of diet (diet contents). The information processing system may be further provided with various management functions, such as for nutrition management. [Solution] An information processing system of the present embodiment comprises: a diet restriction period setting unit that sets a diet restriction period corresponding to diet-related information regarding a predetermined diet of a first user; and a medication notification presentation unit that presents a medication notification on the basis of diet time information indicating the time of intake of the predetermined diet and the diet restriction period that has been set. The diet-related information includes at least one of a plurality of diet type information items indicating the extent of the predetermined diet.
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
71.
HYDROXYPYRROLIDINE DERIVATIVE AND MEDICINAL APPLICATION THEREOF
The present invention provides a target protein degradation-inducing compound that is a bifunctional compound having a portion that binds to VHL, which is a substrate recognition protein of a ubiquitin ligase complex, at one end, and a portion that binds to a target protein at the other end. Specifically, a compound represented by the following structural formula (I):
The present invention provides a target protein degradation-inducing compound that is a bifunctional compound having a portion that binds to VHL, which is a substrate recognition protein of a ubiquitin ligase complex, at one end, and a portion that binds to a target protein at the other end. Specifically, a compound represented by the following structural formula (I):
The present invention provides a target protein degradation-inducing compound that is a bifunctional compound having a portion that binds to VHL, which is a substrate recognition protein of a ubiquitin ligase complex, at one end, and a portion that binds to a target protein at the other end. Specifically, a compound represented by the following structural formula (I):
wherein each symbol is as defined in the present specification, or a pharmacologically acceptable salt thereof.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
This invention provides methods for the treatment of anemia in patients with chronic kidney disease (CKD) using vadadustat (Compound 1), including methods suitable for conversion, correction, and maintenance therapy for patients. For example, methods described herein are durable, with efficacy observed for 24-52 weeks. Methods described herein can be particularly beneficial for patients converting from a previous anemia treatment comprising administration of an erythropoietin stimulating agent (ESA) such as darbepoetin alfa (DA), CKD patients on dialysis (e.g., peritoneal dialysis or hemodialysis), or CKD patients having certain hemoglobin (Hb) levels.
A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
A myoregulin inhibitor such as an antisense oligonucleotide against myoregulin or an anti-myoregulin antibody is used as an active ingredient of a prophylactic or therapeutic agent for a muscle disease such as muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, disused muscular atrophy, and sarcopenia.
A method of treating an oxidative stress disease includes orally or intragastrically administering, to a subject in need thereof, a pharmaceutical composition including edaravone with a time interval from a consumption of a meal by the subject in need thereof to an administration of the pharmaceutical composition to the subject in need thereof. The time interval is 8 hours or longer after the consumption of a high-fat meal, the time interval is 4 hours or longer after the consumption of a standard meal, or the time interval is 2 hours or longer after the consumption of a light meal.
An information processing device includes a data acquisition part that acquires one or more neuromuscular disease-related user data selected from (a) – (k) multiple times in a predetermined period; and an information generation part that generates to-be-provided information to be provided to a predetermined terminal based on the user data. (a) Typing operation-related data, (b) walking-related data, (c) utterance-related data, (d) sleep-related data, (e) breathing-related data, (f) facial expression-related data, (g) fine motor movement-related data, (h) gross motor movement-related data, (i) questionnaire answers regarding disease symptoms, (j) information automatically collected with built-in sensors of devices, and (k) data from medical institutions.
A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
A61B 5/113 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb occurring during breathing
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
Provided herein are methods for reducing, minimizing, or controlling drug-drug interactions resulting from administration of a first drug that is vadadustat (i.e., {[5-(3- chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1)) and a second drug (for example, a drug comprising a multivalent cation such as calcium, iron, magnesium, lanthanum, aluminum, and the like; a statin drug; sulfasalazine; or furosemide), to a subject.
A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
A61K 33/06 - Aluminium, calcium or magnesiumCompounds thereof
A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
A61K 31/22 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A medicament for treatment or prevention of porphyria, comprising 1-{2-[(3S,4R)-1-{[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidin-3-yl]carbonyl}-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylic acid or a pharmaceutically acceptable salt or cocrystal thereof as an active ingredient, wherein the dose of the 1-{2-[(3S,4R)-1-{[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidin-3-yl]carbonyl}-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylic acid or the pharmaceutically acceptable salt or cocrystal thereof is 50 to 500 mg/day.
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
84.
MEDICAL AGENT FOR TREATING OR SUPPRESSING PROGRESSION OF AMYOTROPHIC LATERAL SCLEROSIS
Disclosed is a medical agent that is for treating or suppressing progression of at least one symptom selected from the group consisting of symptoms of amyotrophic lateral sclerosis and symptoms caused by amyotrophic lateral sclerosis in a subject. The medical agent contains 3-methyl-1-phenyl-2-pyrazolin-5-one or a physiologically acceptable salt thereof, or a hydrate or a solvate thereof. The blood uric acid level in the subject before administration of the medical agent is at least 4.2 mg/dL.
A medicine for treating or preventing interstitial lung disease and the disease or symptoms associated with systemic scleroderma in a subject, said medicine containing, as an active ingredient, 1-\{2-[(3S,4R)-1-\{[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidin-3-yl]carbonyl\}-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl\}piperidine-4-carboxylic acid, a pharmaceutically acceptable salt thereof or a co-crystal thereof.
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
The purpose of the present invention is to provide a novel B0AT1 inhibitor. The present invention relates to a compound represented by formula (I): (the symbols in the formula are as described in the description) or a salt thereof. The present invention also relates to a B0AT1 inhibitor comprising said compound and a preventive and/or therapeutic agent for amino acid metabolism diseases such as phenylketonuria, hypertyrosinemia (types 1-3), hypermethioninemia, maple syrup urine disease, homocystinuria, non-ketotic hyperglycinemia, propionic acidemia, methylmalonic acidemia, and isovaleric acidemia that contains said compound.
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 31/223 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-amino acids
A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/401 - ProlineDerivatives thereof, e.g. captopril
A61K 31/429 - Thiazoles condensed with heterocyclic ring systems
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/4402 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/499 - Spiro-condensed pyrazines or piperazines
A61K 31/4995 - Pyrazines or piperazines forming part of bridged ring systems
A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
A61K 31/54 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
A61P 13/02 - Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07C 237/22 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
C07C 317/28 - SulfonesSulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07D 209/30 - IndolesHydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
C07D 211/16 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
C07D 211/46 - Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
C07D 213/68 - One oxygen atom attached in position 4
C07D 215/08 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
C07D 217/06 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ringAlkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
C07D 217/14 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
C07D 217/22 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 233/38 - One oxygen atom with acyl radicals or hetero atoms directly attached to ring nitrogen atoms
C07D 237/08 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 239/26 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07D 241/08 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
C07D 241/12 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 243/08 - Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
C07D 265/30 - 1,4-OxazinesHydrogenated 1,4-oxazines not condensed with other rings
C07D 277/28 - Radicals substituted by nitrogen atoms
C07D 295/185 - Radicals derived from carboxylic acids from aliphatic carboxylic acids
C07D 295/205 - Radicals derived from carbonic acid
C07D 295/215 - Radicals derived from nitrogen analogues of carbonic acid
C07D 307/14 - Radicals substituted by nitrogen atoms not forming part of a nitro radical
C07D 309/04 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
This invention provides method of treating hypertension in a hypertensive subject, the method comprising administering to the subject a CYP 11β2 beta hydroxylase inhibitor once or twiceper day in an amount sufficient to inhibit 50% or more of CYP 11β2 beta hydroxylase's activityfor 40-60% of a 24-hour period to thereby treat hypertension in the hypertensive subject.
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
88.
COMPOUND, METHOD AND PHARMACEUTICAL COMPOSITION FOR REGULATING EXPRESSION OF ATAXIN 3
A modified oligonucleotide having an activity of inhibiting Ataxin 3 expression and having any one of the following nucleobase sequences or a nucleobase sequence of 17 contiguous bases contained in the nucleobase sequences:
A modified oligonucleotide having an activity of inhibiting Ataxin 3 expression and having any one of the following nucleobase sequences or a nucleobase sequence of 17 contiguous bases contained in the nucleobase sequences:
(SEQ ID NO: 239)
(1)
TCGGGTAAGTAGATTTTC,
(SEQ ID NO: 240)
(2)
GAAGTATCTGTAGGCCTA,
(SEQ ID NO: 241)
(3)
GGACTGTATAGGAGATTA,
(SEQ ID NO: 242)
(4)
GGTTATAGGATGCAGGTA,
(SEQ ID NO: 243)
(5)
AGGTTATAGGATGCAGGT,
(SEQ ID NO: 244)
(6)
GAAGCTAAGTAGGTGACT,
(SEQ ID NO: 245)
(7)
TGAAGCTAAGTAGGTGAC,
(SEQ ID NO: 246)
(8)
CCTAGTCACTTTGATAGA,
(SEQ ID NO: 247)
(9)
GGAACATCTTGAGTAGGT,
(SEQ ID NO: 248)
(10)
GGTGTTCAGGGTAGATGT,
(SEQ ID NO: 249)
(11)
GGATACTCTGCCCTGTTC,
(SEQ ID NO: 250)
(12)
GGTGTCAAACGTGTGGTT,
(SEQ ID NO: 251)
(13)
CCGTGTGCTAGTATTTGT,
(SEQ ID NO: 252)
(14)
TAGTAGAGTTTTGCTTGG,
(SEQ ID NO: 253)
(15)
GATGTAGTAGAGTTTTGC,
(SEQ ID NO: 254)
(16)
TGATGTAGTAGAGTTTTG,
(SEQ ID NO: 255)
(17)
CTGATGTAGTAGAGTTTT,
(SEQ ID NO: 256)
(19)
GCAAGTTGGTTTGTGGTA,
(SEQ ID NO: 257)
(20)
TCTAGGCAATTGTGGTGG,
(SEQ ID NO: 258)
(21)
GTAACTCTGCACTTCCCA,
(SEQ ID NO: 259)
(22)
GTCATCCCTATGTCTTAT,
(SEQ ID NO: 260)
(23)
GTCATATGGTCAGGGTAT,
(SEQ ID NO: 261)
(24)
TGTCATATGGTCAGGGTA,
(SEQ ID NO: 262)
(25)
ATGTCATATGGTCAGGGT,
and
(SEQ ID NO: 263)
(26)
TATGTCATATGGTCAGGG.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/7115 - Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
89.
PROPHYLACTIC OR THERAPEUTIC AGENT FOR PHOTODERMATOSIS
A medicament for treating or preventing a condition that is treatable or preventable by promotion of melanin production, such as photodermatoses (excluding porphyria), hypopigmentary disease (excluding vitiligo vulgaris), adverse effects of phototherapy, or gray hair, said medicament comprising a compound represented by general formula [I], or a pharmaceutically acceptable salt or cocrystal thereof, as an active ingredient.
A medicament for treating or preventing a condition that is treatable or preventable by promotion of melanin production, such as photodermatoses (excluding porphyria), hypopigmentary disease (excluding vitiligo vulgaris), adverse effects of phototherapy, or gray hair, said medicament comprising a compound represented by general formula [I], or a pharmaceutically acceptable salt or cocrystal thereof, as an active ingredient.
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
[Problem] To provide an information processing system which performs the estimation of a tardive dyskinesia-like symptom on the basis of facial image information including the facial expression of a user to produce tardive dyskinesia-like symptom information associated with the user and can estimate a tardive dyskinesia-like symptom easily. [Solution] The information processing system according to the present invention is provided with: an image acquisition unit for acquiring information on the facial image of a user which is captured by an imaging unit (i.e., facial image information); and a tardive dyskinesia-like symptom information production unit for producing tardive dyskinesia-like symptom information associated with a tardive dyskinesia-like symptom found on the face of the user on the basis of the acquired facial image information.
A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
Provided is an information processing system for visualizing disease-related information of optic nerve diseases including the neuromyelitis optica spectrum disorder, in order to readily know the state of the NMOSD and, eventually, to enable early detection of a sign of a flare-up from data input by the patient. The information processing system of the present invention comprises: a disease-related information acquiring unit that acquires disease-related information including at least optic nerve disease-related information of a subject; a visualization information-adding unit that adds visualization information, generated on the basis of the disease-related information including the optic nerve disease-related information, to a first diagram representing the shape of at least a part of the body of a human; and a display information generation unit that generates display information including a second diagram obtained by adding the visualization information to the first diagram.
G16H 10/00 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data
A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
The present invention aims to provide a compound acting as a specific agonist for LPA4 receptors, and a pharmaceutical composition containing the compound. The present invention relates to a novel lysophosphatidic acid derivative having an agonistic action on LPA4 receptors and useful for the prophylaxis and/or treatment of diseases associated with angiogenesis abnormalities involving LPA4 receptors, diseases associated with vascular disorders, or the symptoms associated therewith, and a pharmaceutical composition containing the derivative.
Provided is a compound or a pharmaceutically acceptable salt thereof which is superior in an action inducing degradation of BRD4 protein and useful as a therapeutic agent for cancer. A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof:
wherein each symbol is as defined in the DESCRIPTION.
A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
The present invention provides: a novel spiro compound having a TRH-DE inhibition activity and useful for the prevention/treatment of various diseases associated with TRH and/or symptoms associated with the diseases, or a pharmacologically acceptable salt thereof; a method for producing the compound or a pharmacologically acceptable salt thereof; a use of the compound or a pharmacologically acceptable salt thereof; a pharmaceutical composition which contains the compound or a pharmacologically acceptable salt thereof as an active ingredient; and others. The present invention is a compound represented by general formula [I]: [wherein the ring A represents an optionally substituted aryl group, an optionally substituted heteroaryl group or an optionally substituted aliphatic heterocyclic ring group; and R1and R2independently represent an optionally substituted alkyl group, an optionally substituted cycloalkyl group, an optionally substituted alkenyl group, an optionally substituted cycloalkenyl group, an optionally substituted alkynyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted aliphatic heterocyclic ring group which may contain a double bond in a portion of the ring, an optionally substituted amino group, an optionally substituted alkoxy group, or an optionally substituted alkylthio group, or R1and R2 together form a ring] or a pharmacologically acceptable salt thereof.
C07D 205/12 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/429 - Thiazoles condensed with heterocyclic ring systems
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/4427 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems
A61K 31/4436 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/5355 - Non-condensed oxazines containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A61K 31/554 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
A61P 25/04 - Centrally acting analgesics, e.g. opioids
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
